Text Size
25 studies found for:    AMG479

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
AMG479
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
Conditions: Advanced Malignancy;   Advanced Solid Tumors;   Cancer;   Solid Tumors;   Tumors
Intervention: Drug: AMG 479
2 Terminated GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
Conditions: Adenocarcinoma of the Pancreas;   Advanced Solid Tumors;   Cancer;   Cancer of Pancreas;   Cancer of the Pancreas;   Metastases;   Metastatic Cancer;   Metastatic Pancreatic Cancer;   Pancreas Cancer;   Pancreatic Cancer;   Bone Metastases;   Endocrine Cancer;   Oncology;   Oncology Patients;   Solid Tumors;   Advanced Malignancy
Interventions: Drug: AMG 479;   Drug: Placebo;   Drug: gemcitabine
3 Terminated Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
Condition: Advanced Squamous Non-Small Cell Lung Cancer
Interventions: Biological: AMG 479;   Drug: Carboplatin;   Drug: Paclitaxel
4 Recruiting A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer
Condition: Advanced Solid Tumors
Intervention: Drug: AMG 479, Everolimus, Panitumumab
5 Completed A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer
Conditions: Lung Cancer;   Small Cell Lung Cancer;   Solid Tumors;   Extensive-stage Small Cell Lung Cancer
Interventions: Drug: AMG 479 in combination with Cisplatin/Etoposide;   Drug: AMG 479 in combination with Carboplatin/Etoposide;   Drug: Placebo in combination with Cisplatin/Etoposide;   Drug: AMG 102 in combination with Cisplatin/Etoposide;   Drug: Placebo in combination with Carboplatin/Etoposide;   Drug: AMG 102 in combination with Carboplatin/Etoposide
6 Active, not recruiting Panitumumab Combination Study With AMG 102 or AMG 479 in Wild-type KRAS mCRC
Conditions: Colon Cancer;   Colorectal Cancer;   Gastrointestinal Cancer;   Metastatic Colorectal Cancer;   Rectal Cancer
Interventions: Drug: Panitumumab + AMG 102;   Drug: Panitumumab + AMG 479;   Drug: AMG 479;   Drug: AMG 102;   Drug: Panitumumab
7 Terminated AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
Conditions: Colorectal Cancer;   Locally Advanced;   Metastatic Cancer;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Sarcoma;   Solid Tumors
Interventions: Biological: AMG 479;   Biological: AMG 655
8 Active, not recruiting AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor;   Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Intervention: Drug: AMG 479
9 Recruiting Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors
Condition: Neoplasm Metastases
Intervention: Drug: RAD001 + AMG479
10 Completed A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors
Conditions: Askin's Tumors;   Desmoplastic Small Round Cell Tumors;   Estraosseous Ewing's Tumor;   Ewing's Family Tumor;   Ewing's Sarcoma;   Primitive Neuroectodermal Tumors (PNETs);   Sarcoma
Intervention: Drug: AMG 479
11 Recruiting Open Label Extension Study of Conatumumab and AMG 479
Conditions: Advanced Solid Tumors;   Carcinoid;   Colorectal Cancer;   Locally Advanced;   Lymphoma;   Metastatic Cancer;   Non-Small Cell Lung Cancer;   Sarcoma;   Solid Tumors
Interventions: Drug: FOLFOX6;   Biological: Conatumumab;   Biological: Ganitumab;   Biological: Bevacizumab
12 Recruiting A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Conditions: KRAS Mutated Colorectal Adenocarcinoma.;   Metastatic Pancreatic Adenocarcinoma;   BRAF Mutated Melanoma
Intervention: Drug: MEK162 + AMG 479
13 Completed Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
Condition: Metastatic Colorectal Cancer
Interventions: Other: FOLFIRI;   Biological: AMG 655;   Other: Placebo;   Biological: AMG 479
14 Completed A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Metastatic Pancreatic Cancer;   Pancreatic Cancer
Interventions: Other: Placebo;   Drug: AMG 479;   Drug: AMG 655
15 Withdrawn Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab
Condition: Breast Cancer
Interventions: Drug: AMG 479;   Drug: Trastuzumab
16 Recruiting A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
Conditions: PIK3CA Mutated Advanced Solid Tumors,;   PIK3CA Amplified Advanced Solid Tumors
Interventions: Drug: BYL719;   Drug: AMG 479
17 Completed A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
Conditions: Breast Cancer;   Breast Tumors;   Metastatic Cancer
Intervention: Drug: AMG 479 or placebo administered with either exemestane or fulvestrant
18 Active, not recruiting Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: AMG 479;   Drug: AMG 479 Placebo
19 Active, not recruiting Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
Condition: Ovarian Neoplasms
Intervention: Biological: AMG 479
20 Active, not recruiting Ph2 Biomarker (Mechanism of K-ras Dependency) in Wt KRAS Metastatic Colorectal Cancer Patients
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab plus AMG 479;   Drug: Panitumumab plus Irinotecan
To Top

Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results
† Indicates status has not been verified in more than two years